Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Leases (2019 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Current Leases for 8 consecutive years, with $487000.0 as the latest value for Q1 2026.

  • For Q1 2026, Current Leases rose 29.18% year-over-year to $487000.0; the TTM value through Mar 2026 reached $487000.0, up 29.18%, while the annual FY2025 figure was $470000.0, 0.21% changed from the prior year.
  • Current Leases hit $487000.0 in Q1 2026 for Syndax Pharmaceuticals, up from $470000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $1.0 million in Q1 2024 and bottomed at $299000.0 in Q2 2022.
  • Average Current Leases over 5 years is $607000.0, with a median of $471000.0 recorded in 2022.
  • Year-over-year, Current Leases surged 220.07% in 2023 and then plummeted 64.93% in 2025.
  • Syndax Pharmaceuticals' Current Leases stood at $434000.0 in 2022, then soared by 138.48% to $1.0 million in 2023, then plummeted by 54.49% to $471000.0 in 2024, then dropped by 0.21% to $470000.0 in 2025, then increased by 3.62% to $487000.0 in 2026.
  • According to Business Quant data, Current Leases over the past three periods came in at $487000.0, $470000.0, and $329000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.